Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

JUMPGATE AB Press Release from the Annual General Meeting in Jumpgate AB June 18, 2024

Jumpgate AB (the “Company”) held its Annual General Meeting on Tuesday June 18, 2024 in the Company premises in Visby. The Annual General Meeting resolved in accordance with all previously announced proposed resolutions. Below follows a summary of the main resolutions that were made. The Company´s income statement and balance sheet was adopted and it was resolved to balance the Company´s loss according to the approved balance sheet. The board members and the CEO were discharged from liability in accordance with the recommendation from the auditors. Martin Ekdal, Marcus Jacobs,

RayStation Used for First-Ever Radiotherapy Treatment with Hitachi’s OXRAY system

RaySearch Laboratories AB (publ) is pleased to announce a milestone in radiotherapy technology where RaySearch’s RayStation®* was used for the world’s first clinical treatment using OXRAY, a new treatment machine from Hitachi. The event took place on June 17 at Narita Memorial Hospital in Toyohashi, Japan.OXRAY represents a pioneering radiotherapy system featuring a Gimbal-mounted beam delivery system. RayStation was used to drive its motion tracking functionality, dual-source CBCT image-guided radiotherapy for precise patient positioning, and dynamic swing arc capabilities. Developed in

Salmon Evolution ASA: Contemplated Private Placement and Increased Debt Financing

18 June 2024: Salmon Evolution ASA (”Salmon Evolution” or the “Company”) announces that it has engaged Arctic Securities AS, DNB Markets, a part of DNB Bank ASA, and Nordea Bank Abp, filial i Norge as Joint Global Coordinators and Joint Bookrunners (together the “Managers”) to advise on and effect a contemplated private placement (the “Private Placement”) of new ordinary shares in the Company (the “Offer Shares”) raising gross proceeds of approximately NOK 350 million. The price per Offer Share in the Private Placement (“Offer Price”) will be set by the Company’s board of directors (the “

ChromoGenics AB (publ) publishes the Annual Report for 2023

ChromoGenics AB  (publ) today announces that it has published the Annual Report for 2023.The Annual Report, which is attached to the press release, is also available on the company website, https://chromogenics.com/annual-reports/The Annual Report can also be ordered from the company and distributed by post to the shareholders who request it.  Contact: Fredrik Fränding, CEOAnne-Marie Gullman, CFO & Head of Investor RelationsTel: +46 (0) 18 430 0430 E-mail: info@chromogenics.com ChromoGenics This statement has been made in a Swedish and

#24-220 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

Disclosure under Chapter 9, Section 10 of the Securities Markets Act (Cor Group Oy)

Nightingale Health Plc Company release 18 June 2024 at 5:25 p.m. (EEST)   Nightingale Health Plc (“Nightingale Health”) has received a notification on 18 June 2024 according to Chapter 9, Section 5 of the Finnish Securities Markets Act, stating that Cor Group Oy’s ownership of shares exceeds 10% of all shares and votes exceed 10% of all votes in Nightingale Health. Cor Group Oy's ownership and votes exceeded the notification threshold before 19 April 2024. The notification of exceeding the ownership and voting right threshold is retroactive because an amendment to the

Oblique Therapeutics and the KTH Royal Institute of Technology (KTH) have entered into a strategic collaboration to analyse protein structures using supercomputers.

Stockholm, Sweden - 10 June 2024 - Oblique Therapeutics, a leading biotechnology company specialising in the development of new drug candidates, is pleased to announce today that they have entered into an agreement with the KTH Royal Institute of Technology to utilise KTH’s state-of-the-art supercomputer resources for analysing protein structures. This partnership aims to accelerate research and development in the area of innovative treatments for various illnesses. The PDC Center for High Performance Computing (PDC) at KTH hosts the most powerful supercomputer within the National

Disclosure under Chapter 9, Section 10 of the Securities Markets Act (Pasi Soininen)

Nightingale Health Plc Company release 18 June 2024 at 5:15 p.m. (EEST) Nightingale Health Plc (“Nightingale Health”) has received a notification on 18 June 2024 according to Chapter 9, Section 5 of the Finnish Securities Markets Act, stating that Pasi Soininen’s ownership of shares exceeds 5 % of all shares and votes exceed 20 % of all votes in Nightingale Health. Pasi Soininen’s ownership and votes exceeded the notification threshold before 19 April 2024. The notification of exceeding the ownership and voting right threshold is retroactive because an amendment to the

Situation update Aixia Group AB (publ)

Mölndal                                                                                     2024-06-18 Today marks an important milestone for Aixia, as we officially begin trading our share in the US on OTC Markets. (www.otcmarkets.com/stock/AIXAF/news) We are proud to announce a fantastic start to the year, with significant increases in both revenue and profit since the previous year and significant operational developments that have positioned us for continued success. Here follows an update on our current status and future prospects. Fantastic start to the yearWe have experienced

Disclosure under Chapter 9, Section 10 of the Securities Markets Act (Teemu Suna)

Nightingale Health Plc Company release 18 June 2024 at 5:05 p.m. (EEST)   Nightingale Health Plc (“Nightingale Health”) has received a notification on 18 June 2024 according to Chapter 9, Section 5 of the Finnish Securities Markets Act, stating that Teemu Suna’s votes exceed 10 % of all votes in Nightingale Health. Teemu Suna’s votes exceeded the notification threshold before April 19, 2024. The notification of exceeding the voting right threshold is retroactive because an amendment to the Securities Markets Act entered into force on 19 April 2024, according to which the

Circio Holding ASA - Approval and publication of prospectus for the rights issue

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, 18 June 2024: Reference is made to the stock exchange announcements made by Circio Holding ASA (the "Company") on 29 May 2024, whereby the Company published the terms of the contemplated rights issue (the "Rights Issue") and related

Circio Holding ASA - Updated key information relating to the rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, 18 June 2024: Reference is made to the stock exchange announcement published by Circio Holding ASA (the "Company") on 29 May 2024 with key information relating to the rights issue in the Company (the "Rights Issue"). Please see

Circio Holding ASA - Updated information to the notice of annual general meeting 2024

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, 18 June 2024: Reference is made to the notice of the annual general meeting of Circio Holding ASA published on 29 May 2024 and the annual general meeting to be held on Wednesday 19 June 2024 at 10:00 hours (CEST) as a physical meeting at the

SSAB’s updated climate goals approved by the Science Based Targets initiative

SSAB’s near- and long-term carbon emissions reduction targets have been approved by the Science Based Targets initiative (SBTi). Approval means that the targets are scientifically based and in line with the SBTi’s raised requirements for companies to deliver on the goal of limiting global warming to 1.5°C. SSAB’s now validated long-term target is to reach net-zero greenhouse gas emissions for Scope 1, Scope 2 and Scope 3 by 2045*. The updated near-term target is a reduction of 48 percent in greenhouse gas emissions in Scope 1, Scope 2 and parts of Scope 3 by 2033 compared with

Perineal cut reduces the risk of serious birth injury

In first-time mothers requiring vacuum-assisted delivery, a lateral episiotomy (angled cut) in the tissue between the vaginal and anal opening more than halves the risk of obstetric anal sphincter injury, a severe form of perineal trauma between the vulva and anus. This according to a randomised clinical study led by researchers at Karolinska Institutet and Stockholm’s Danderyd Hospital, the results of which are published in The BMJ.Obstetric Anal Sphincter Injury (OASI), which involves the anal sphincter muscles, can lead to anal incontinence with difficulties retaining gas and faeces. It

Raisio plc: Managers´ transactions

Raisio plc Managers´ transactions 18 June 2024   MANAGERS’ TRANSACTIONS   Person subject to the notification requirement Name: Arto Tiitinen Position: Member of the Board/Deputy member Issuer: Raisio Oyj LEI: 74370083282NHIP4QD02   Notification type: INITIAL NOTIFICATION Reference number: 66610/5/4 ____________________________________________   Transaction date: 2024-06-18 Outside a trading venue Instrument type: SHARE ISIN: FI0009002943 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE   Transaction details (1): Volume:

Raisio plc: Managers´ transactions

Raisio plc Managers´ transactions 18 June 2024   MANAGERS’ TRANSACTIONS   Person subject to the notification requirement Name: Tero Hemmilä Position: Member of the Board/Deputy member Issuer: Raisio Oyj LEI: 74370083282NHIP4QD02   Notification type: INITIAL NOTIFICATION Reference number: 66616/4/4 ____________________________________________   Transaction date: 2024-06-18 Outside a trading venue Instrument type: SHARE ISIN: FI0009002943 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE   Transaction details (1): Volume:

Raisio plc: Managers´ transactions 18 June 2024

Raisio plc Managers´ transactions 18 June 2024   MANAGERS’ TRANSACTIONS   Person subject to the notification requirement Name: Leena Niemistö Position: Member of the Board/Deputy member Issuer: Raisio Oyj LEI: 74370083282NHIP4QD02   Notification type: INITIAL NOTIFICATION Reference number: 66628/4/4 ____________________________________________   Transaction date: 2024-06-18 Outside a trading venue Instrument type: SHARE ISIN: FI0009002943 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE   Transaction details (1): Volume:

Raisio plc: Managers´ transactions

Raisio plc Managers´ transactions 18 June 2024   MANAGERS’ TRANSACTIONS   Person subject to the notification requirement Name: Lauri Sipponen Position: Member of the Board/Deputy member Issuer: Raisio Oyj LEI: 74370083282NHIP4QD02   Notification type: INITIAL NOTIFICATION Reference number: 66637/4/4 ____________________________________________   Transaction date: 2024-06-18 Outside a trading venue Instrument type: SHARE ISIN: FI0009002943 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE   Transaction details (1): Volume:

Raisio plc: Managers´ transactions

Raisio plc Managers´ transactions 18 June 2024   MANAGERS’ TRANSACTIONS   Person subject to the notification requirement Name: Ann-Christine Sundell Position: Member of the Board/Deputy member Issuer: Raisio Oyj LEI: 74370083282NHIP4QD02   Notification type: INITIAL NOTIFICATION Reference number: 66639/4/4 ____________________________________________   Transaction date: 2024-06-18 Outside a trading venue Instrument type: SHARE ISIN: FI0009002943 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE   Transaction details (1):

Raisio plc: Managers´ transactions

Raisio plc Managers´ transactions 18 June 2024   MANAGERS’ TRANSACTIONS   Person subject to the notification requirement Name: Pekka Tennilä Position: Member of the Board/Deputy member Issuer: Raisio Oyj LEI: 74370083282NHIP4QD02   Notification type: INITIAL NOTIFICATION Reference number: 66645/4/4 ____________________________________________   Transaction date: 2024-06-18 Outside a trading venue Instrument type: SHARE ISIN: FI0009002943 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE   Transaction details (1): Volume:

Experts from Dicot Pharma's clinical study behind submitted abstract

Uppsala, Sweden, June 18, 2024. The statistical analysis of Dicot Pharma's phase 1 data is now completed, reinforcing and deepening the results the company communicated in April after the end of the study. The results of the analysis will be published in an abstract submitted to North America's largest conference in the field and featuring some of the most prominent names within sexual medicine as co-authors.Dicot Pharma's statistical analysis of the Phase 1 study is completed. The analysis reinforces and deepens the results that were communicated instantly after the end of the study in

Terrafame has started uranium recovery

Terrafame has on 18 June 2024 started recovering natural uranium on its industrial site in Sotkamo, Finland. Before the recovery was commissioned, the Finnish Radiation and Nuclear Safety Authority (STUK) conducted a commissioning inspection at the uranium recovery plant and found that the plant can be commissioned safely.  The company’s production process enables the low concentration of natural uranium found in the ore to be used as a by-product. The uranium recovered by Terrafame will be transported abroad for further processing, after which it will be used in nuclear energy

Disclosure under Chapter 9, Section 10 of the Securities Markets Act (Antti Kangas)

Nightingale Health Plc Company release 18 June 2024 at 3:20 p.m. (EEST)   Nightingale Health Plc (“Nightingale Health”) has received a notification on 18 June 2024 according to Chapter 9, Section 5 of the Finnish Securities Markets Act, stating that Antti Kangas’s ownership of shares exceeds 5 % of all shares and votes exceed 20 % of all votes in Nightingale Health. Antti Kangas’s ownership and votes exceeded the notification threshold before April 19, 2024. The notification of exceeding the ownership and voting right threshold is retroactive because an amendment to the

There are no items matching the current filter
There are no more items matching the current filter
Back to top